DrugPatentWatch Database Preview
Larotrectinib sulfate - Generic Drug Details
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What are the generic drug sources for larotrectinib sulfate and what is the scope of freedom to operate?
Larotrectinib sulfate
is the generic ingredient in one branded drug marketed by Bayer Hlthcare and Bayer Healthcare, and is included in two NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Larotrectinib sulfate has one hundred and thirty-five patent family members in forty-one countries.
Two suppliers are listed for this compound.
Summary for larotrectinib sulfate
| International Patents: | 135 |
| US Patents: | 12 |
| Tradenames: | 1 |
| Applicants: | 2 |
| NDAs: | 2 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 15 |
| Patent Applications: | 27 |
| DailyMed Link: | larotrectinib sulfate at DailyMed |
Synonyms for larotrectinib sulfate
| (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
| (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide sulfate |
| 1-Pyrrolidinecarboxamide, N-(5-((2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxy-, (3S)-, sulfate (1:1) |
| 1-Pyrrolidinecarboxamide, N-[5-[(2R)-2-(2,5-difluorophenyl)-1-pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxy-, (3S)-, sulfate (1:1) |
| 1223405-08-0 |
| ARRY-470 |
| ARRY-470 sulfate |
| CHEMBL3989939 |
| CS-5314 |
| D11138 |
| HY-12866A |
| Larotrectinib (LOXO-101) sulfate |
| Larotrectinib sulfate (USAN) |
| Larotrectinib sulfate [USAN] |
| LOXO-101 (sulfate) |
| LOXO-101 sulfate |
| LOXO-101(sulfate) |
| PXHANKVTFWSDSG-QLOBERJESA-N |
| RDF76R62ID |
| s7960 |
| SCHEMBL2239598 |
| UNII-RDF76R62ID |
US Patents and Regulatory Information for larotrectinib sulfate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-002 | Nov 26, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Bayer Hlthcare | VITRAKVI | larotrectinib sulfate | CAPSULE;ORAL | 210861-001 | Nov 26, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for larotrectinib sulfate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | 3106463 | Start Trial |
| South Korea | 20170116220 | Start Trial |
| Mexico | 2018012165 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
